The basis of chronic hepatitis B treatment is antiviral therapy, the goal of which is to effectively inhibit viral replication, delay disease progression, reduce hepatocellular inflammation and liver fibrosis, prevent and stop cirrhosis and hepatocellular carcinoma from occurring, thereby prolonging the survival time and improving the quality of life of patients. At present, there are two major classes of hepatitis B antiviral drugs recognized by experts, five in total, namely interferon (ordinary interferon, long-acting interferon) and nucleoside (lamivudine, adefovir, telbivudine, entecavir). So how do you choose antiviral drugs for hepatitis B for patients? The choice of hepatitis B antiviral drugs should focus on three main elements: efficacy, risk of drug resistance and safety. The hepatitis B anti-viral drugs are selected on the basis of their efficacy, keeping the virus unpredictable Chronic hepatitis B is a chronic disease caused by hepatitis B virus infection, and the continuous replication of hepatitis B virus will cause inflammation and damage to liver tissue, so you need to choose hepatitis B anti-viral drugs that can strongly and durably reduce the virus, so that the virus can be continuously suppressed at the lowest possible level, thus controlling the disease in a lasting and stable manner and curbing the progress of the disease towards cirrhosis and liver cancer. The second is drug resistance. The second is drug resistance, the incidence of drug resistance is as low as possible Drug resistance is still an unavoidable difficulty in the current antiviral treatment of hepatitis B. Once encountered, drug resistance not only leads to the development of hepatitis B, but also leads to the development of liver cancer. Once drug resistance is encountered, not only does it lead to the failure of the hepatitis B antiviral drugs and the rebound of the virus, but patients will also suffer additional treatment costs in the process of constantly adding and changing medications. The data shows that the extra cost of treatment that patients need to bear after the onset of drug resistance, only the cost of specialist visits, inpatient treatment, drug resistance testing, etc., will cause an additional cost of about 4,000 yuan for each patient in the first year after the onset of drug resistance. And these do not include the cost of the treatment drug itself, the patient’s transportation costs to the doctor, and the cost of lost work. Experts say we hope to minimize the likelihood of drug resistance by choosing the right hepatitis B antiviral drug. Three look at the safety, quality assurance is important Selecting hepatitis B antiviral drugs is the same as choosing other drugs, you need to understand the adverse reactions, clinical data, experience in using the drug and the quality of the product, because the treatment cycle of chronic hepatitis B is long, the quality and safety of the drug is particularly important. In addition to the data from large-scale clinical trials before the drug is introduced, the accumulation of data from the actual clinical treatment of the drug is also an important basis for ensuring the fair use of the drug. Patients should try to choose a reliable hepatitis B antiviral drug that is supported by a large amount of clinical trial data and has been verified by long-term clinical practice. Finally, experts emphasize that following the above three principles for choosing hepatitis B antiviral drugs can help patients minimize the rebound of disease due to poor efficacy, side effects or drug resistance during the treatment process, and help patients enhance their confidence and compliance with treatment, thus improving their quality of life and returning to a relaxed life.